Development

Avid Bioservices has expanded its viral vector development and manufacturing facility with the addition of analytical and process development suites.

Orbit Discovery has been awarded the Innovate UK Grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery.

Batavia Biosciences is expanding its headquarters and R&D capabilities in its Netherlands facility.

A new polymer surface material has been invented by researchers in Sweden that uses electrical signals to both capture and release biomolecules.

Precision BioSciences has released clinical trial data on CAR T therapy candidates PBCAR0191, PBCAR19B, and PBCAR269A.

One get obtain a clearer assessment of gene-editing outcomes through more exacting analytical tools.

Thermo Fisher Scientific and Qatar Genome Program will use custom genotyping arrays to accelerate genomic research in Qatar.

Having a clear clinical strategy early on can shave time off overall development projects.

Advances in genomics tools can lead to quicker biotherapeutic development.

With recent approvals of bispecific antibodies, these complex molecules are fast moving out of the research box and into clinical pipelines.

Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.

Lubrizol has launched Apisolex technology to improve solubility and simplify the manufacturing of parenteral drug products.

Investment has been made into a new science hub at the University of Edinburgh for the development of treatments for lung infections and future pandemics.

Demand for outsourced services of technical R&D activities is increasing.

To build trust and ensure a high-quality product, companies must be sure their contracts are firm and their lines of communication even firmer.

The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.

The agency’s Center for Drug Evaluation and Research has launched the new program to increase development of treatment options for patients with rare diseases.

Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.

AstraZeneca has announced plans to open a new strategic R&D center in Cambridge, MA, which will also serve as Alexion’s headquarters.

An increasingly complex development pipeline and industry considerations, such as sustainability, are leading to a greater need for more efficient separation and purification in downstream processing.

Complex hurdles complicate the development of emerging therapies.

Plant-based manufacturing technology gains mainstream edge in biopharmaceutical production.

Advances in therapeutic modalities and an increase in molecular complexity have led to the need for an evolution in drug delivery approaches over the years.

Johnson & Johnson has launched its next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town.

The European Investment Bank has provided €15 million to fund coronavirus research at IRBM.